Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shaun Goodyear"'
Autor:
Adam S. Kittai, Scott Best, Bria Thurlow, Vi Lam, Taylor Hashiguchi, Shaun Goodyear, Daniel O. Persky, Craig Okada, Byung Park, Stephen E. Spurgeon, Alexey V. Danilov
Publikováno v:
Haematologica, Vol 106, Iss 7 (2021)
Externí odkaz:
https://doaj.org/article/831868bb6ee24e4dad3f1c03097fdbda
Autor:
Worapol Ngamcherdtrakul, Thanapon Sangvanich, Shaun Goodyear, Moataz Reda, Shenda Gu, David J. Castro, Primana Punnakitikashem, Wassana Yantasee
Publikováno v:
Bioengineering, Vol 6, Iss 1, p 23 (2019)
Multiparametric and high-content protein analysis of single cells or tissues cannot be accomplished with the currently available flow cytometry or imaging techniques utilizing fluorophore-labelled antibodies, because the number of spectrally resolvab
Externí odkaz:
https://doaj.org/article/0857a65cfdca4c5ba27f907408d6a03e
Autor:
Brie Chun, Shaun Goodyear, Travis Rice-Stitt, Lisa Karstens, Erin Dahl, Allen Li, Evthokia Hobbs, Mitri Zahi
Publikováno v:
Cancer Research. 83:P1-04
Background: Greater gut microbiome diversity is observed in patients with a clinical response to immune checkpoint inhibitor (ICI) therapy in solid tumors and in preclinical models targeting the gut microbiome is a promising strategy to improve ICI e
Autor:
Charles D. Lopez, Adel Kardosh, Emerson Yu-sheng Chen, Guillaume Joe Pegna, Skye C. Mayo, Robert Eil, Erin W. Gilbert, Flavio G. Rocha, Nima Nabavizadeh, Aaron Grossberg, Alexander Guimaraes, Bryan Foster, Brian Brinkerhoff, Shaun Goodyear, Dove Keith, Gordon B. Mills, Rosalie C. Sears, Jonathan Brody, Brett C. Sheppard
Publikováno v:
Journal of Clinical Oncology. 41:TPS776-TPS776
TPS776 Background: Neoadjuvant chemotherapy (NAC) and/or chemo-RT may confer benefit to patients with localized PDAC, by better tolerability, tumor down-staging, and increased R0 resections. mFFX or GA are the current NAC backbones; however, a lack o
Autor:
Charles D. Lopez, Adel Kardosh, Emerson Yu-sheng Chen, Guillaume Joe Pegna, Alexander Guimaraes, Bryan Foster, Brian Brinkerhoff, Shaun Goodyear, Erin Taber, Brindha Rajagopalan, Johnson Vo, Kiara Siex, Brett Johnson, Danielle Galipeau, Sidney Huszti, Dove Keith, Brett C. Sheppard, Jonathan Brody, Rosalie C. Sears, Gordon B. Mills
Publikováno v:
Journal of Clinical Oncology. 41:TPS781-TPS781
TPS781 Background: Even as the number of targeted agents increases, therapeutic options for PDAC patients remain limited by a lack of biomarkers that can predict the potential clinical benefit of single agents or combination therapeutic strategies. T
Autor:
Malinda T West, Shaun Goodyear, Andy Kaempf, Thomas Kartika, Jessica Ribkoff, Evthokia Hobbs, Zahi Ibrahim Mitri
Publikováno v:
Journal of Clinical Oncology. 40:1054-1054
1054 Background: Combination of CDKi with endocrine therapy is a key treatment for mHRBC due to survival benefit and favorable safety profile. However, progressive disease inevitably develops and outcomes after CDKi discontinuation (dc) are not well-
Autor:
Brett S Walker, Adel Kardosh, Robert Eil, Melissa Wong, Alice Fung, Jonathan Brody, Sudarshan Anand, Christopher L. Corless, Lissi Hansen, Susan Rosenkranz, Byung Park, Emerson Yu-sheng Chen, Anna Jackson, Johnson Vo, Anne Fahlman, Flavio G. Rocha, Charles D. Lopez, Shaun Goodyear, Skye C. Mayo
Publikováno v:
Journal of Clinical Oncology. 40:TPS500-TPS500
TPS500 Background: The majority of patients with intrahepatic cholangiocarcinoma (ICC) present with advanced liver dominant disease rendering them unresectable. The current standard of care supports palliative treatment of unresectable ICC with gemci